SOPHiA GENETICS SA (NASDAQ:SOPH – Get Free Report) saw strong trading volume on Thursday. Approximately 549,217 shares changed hands during mid-day trading, an increase of 55% from the average daily volume of 354,314 shares. The stock last traded at $7.24 and had previously closed at $7.47.
Analysts Set New Price Targets
A number of equities analysts have recently issued reports on SOPH shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of SOPHiA GENETICS in a research note on Thursday, October 15th. BTIG Research raised their price target on shares of SOPHiA GENETICS from $8.00 to $9.00 and gave the stock a “buy” rating in a report on Wednesday, August 5th. Finally, HC Wainwright reiterated a “buy” rating and issued a $14.00 price target on shares of SOPHiA GENETICS in a report on Monday, October 12th. Three research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $10.00.
Read Our Latest Research Report on SOPHiA GENETICS
SOPHiA GENETICS Trading Down 6.8%
The business’s fifty day simple moving average is $7.62 and its two-hundred day simple moving average is $6.09. The company has a market cap of $583.83 million, a price-to-earnings ratio of -6.40 and a beta of 1.09. The company has a quick ratio of 2.16, a current ratio of 2.29 and a debt-to-equity ratio of 0.70.
SOPHiA GENETICS (NASDAQ:SOPH – Get Free Report) last released its quarterly earnings results on Tuesday, November 3rd. The company reported ($0.24) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.04). The company had revenue of $24.27 million for the quarter, compared to analysts’ expectations of $24.03 million. SOPHiA GENETICS had a negative return on equity of 128.69% and a negative net margin of 89.18%. On average, equities analysts predict that SOPHiA GENETICS SA will post -0.94 EPS for the current year.
Insider Activity at SOPHiA GENETICS
In related news, Chairman Jurgi Camblong sold 8,500 shares of SOPHiA GENETICS stock in a transaction that occurred on Monday, October 12th. The stock was sold at an average price of $7.26, for a total transaction of $61,710.00. Following the completion of the transaction, the chairman directly owned 3,387,150 shares in the company, valued at $24,590,709. The trade was a 0.25% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Philippe Menu sold 5,000 shares of the company’s stock in a transaction on Monday, October 12th. The shares were sold at an average price of $7.26, for a total value of $36,300.00. Following the completion of the sale, the insider owned 195,993 shares in the company, valued at $1,422,909.18. This represents a 2.49% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 148,162 shares of company stock valued at $1,199,254 in the last 90 days. 4.88% of the stock is owned by corporate insiders.
Hedge Funds Weigh In On SOPHiA GENETICS
Institutional investors have recently added to or reduced their stakes in the company. Maven Securities LTD acquired a new position in SOPHiA GENETICS during the 2nd quarter worth $866,000. Sowell Financial Services LLC bought a new position in SOPHiA GENETICS during the 3rd quarter worth approximately $2,865,000. AWM Investment Company Inc. bought a new position in SOPHiA GENETICS during the second quarter worth $9,809,000. Sei Investments Co. bought a new stake in shares of SOPHiA GENETICS during the 1st quarter valued at about $1,772,000. Finally, Hennion & Walsh Asset Management Inc. acquired a new stake in SOPHiA GENETICS in the second quarter worth $567,000. Institutional investors and hedge funds own 31.59% of the company’s stock.
SOPHiA GENETICS Company Profile
SOPHiA GENETICS is a healthcare technology company that develops data-analysis tools for genomics and other complex health data. Its cloud-based SOPHiA DDM platform uses artificial intelligence and analytics to help healthcare and research organizations interpret data and support clinical and scientific decision-making. The platform and related applications are used in areas including oncology, rare diseases and inherited conditions. The company serves hospitals, laboratories, biopharmaceutical companies and research organizations, with a presence across international markets.
Read More
- Five stocks we like better than SOPHiA GENETICS
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
- 3 Niche ETFs Are Beating the S&P 500, and Their Strategies Are Anything but Typical
Receive News & Ratings for SOPHiA GENETICS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SOPHiA GENETICS and related companies with MarketBeat.com's FREE daily email newsletter.
